Editing Myasthenia gravis (section)

=== Subgroup classification ===
{| class="wikitable" style = "float: right; margin-left:15px; text-align:center"
|+ '''Myasthenia Gravis Foundation of America Clinical Classification'''<ref>{{Cite book |title=Myasthenia Gravis and Related Disorders |vauthors=Wolfe GI, Barohn RJ |year=2009 |isbn=978-1-58829-852-2 |pages=293–302 |chapter=Myasthenia Gravis: Classification and Outcome Measurements |doi=10.1007/978-1-59745-156-7_18}}</ref>
|-
! Class !! Description
|-
| I || Any eye muscle weakness, possible [[ptosis (eyelid)|ptosis]], no other evidence of muscle weakness elsewhere
|-
| II || Eye muscle weakness of any severity, mild weakness of other muscles
|-
| IIa || Predominantly limb or axial muscles
|-
| IIb || Predominantly bulbar and/or respiratory muscles
|-
| III || Eye muscle weakness of any severity, moderate weakness of other muscles
|-
| IIIa || Predominantly limb or axial muscles
|-
| IIIb || Predominantly bulbar and/or respiratory muscles
|-
| IV || Eye muscle weakness of any severity, severe weakness of other muscles
|-
| IVa || Predominantly limb or axial muscles
|-
| IVb || Predominantly bulbar and/or respiratory muscles
|-
| V || Intubation needed to maintain airway
|}
When diagnosed with MG, patient can be stratified into distinct subgroups based on the clinical features and serological status, e.g. affected muscle group, age of onset, thymic abnormalities, and profile of serum autoantibodies.<ref>{{Cite journal |last1=Meriggioli |first1=Matthew N |last2=Sanders |first2=Donald B |date=May 2009 |title=Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity |journal=The Lancet Neurology |volume=8 |issue=5 |pages=475–490 |doi=10.1016/S1474-4422(09)70063-8 |pmc=2730933 |pmid=19375665}}</ref>

Based on the affected muscle group, patients can be sub-grouped into ocular MG or generalized MG. Ocular MG is characterized by exclusively ocular symptoms, droopy eyelids, or double vision. Generalized MG has muscle weakness with a variable combination of the bulbar, axial, or limb and respiratory muscles.<ref>{{Cite journal |last1=Gilhus |first1=Nils Erik |last2=Verschuuren |first2=Jan J |date=October 2015 |title=Myasthenia gravis: subgroup classification and therapeutic strategies |url=https://doi.org/10.1016/S1474-4422(15)00145-3 |journal=The Lancet Neurology |volume=14 |issue=10 |pages=1023–1036 |doi=10.1016/s1474-4422(15)00145-3 |issn=1474-4422 |pmid=26376969}}</ref>

Patients can also be sub-grouped by the age of onset: juvenile-onset MG (onset age ≤ 18 years of age), early-onset MG (EOMG; 19–50 years of age), late-onset MG (LOMG; onset > 50 years of age), and very late-onset (VLOMG; onset age ≥ 65 years of age).<ref>{{Cite journal |last1=Punga |first1=Anna Rostedt |last2=Maddison |first2=Paul |last3=Heckmann |first3=Jeannine M |last4=Guptill |first4=Jeffrey T |last5=Evoli |first5=Amelia |date=February 2022 |title=Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders |url=https://linkinghub.elsevier.com/retrieve/pii/S1474442221002970 |journal=The Lancet Neurology |volume=21 |issue=2 |pages=176–188 |doi=10.1016/S1474-4422(21)00297-0 |pmid=35065040}}</ref>

The subgroup of the autoantibody profile includes AChR seropositive, MuSK seropositive, LRP4 seropositive, and agrin seropositive.<ref>{{Cite journal |last1=Koneczny |first1=Inga |last2=Herbst |first2=Ruth |date=2019-07-02 |title=Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture |journal=Cells |volume=8 |issue=7 |pages=671 |doi=10.3390/cells8070671 |issn=2073-4409 |pmc=6678492 |pmid=31269763 |doi-access=free}}</ref>